Effectiveness, safety and adherence to therapy with Elicea Q-Tab in real clinical practice

Oleichik I.V.; Shishkovskaia T.I.; Baranov P.A.

doi:https://doi.org/10.17116/jnevro202312311246

Oleichik I.V.

Mental Health Research Center

ORCID: 0000-0002-8344-0620

Shishkovskaia T.I.

Mental Health Research Center

ORCID: 0000-0002-4423-4007

Baranov P.A.

Mental Health Research Center

ORCID: 0000-0002-4423-4007

Effectiveness, safety and adherence to therapy with Elicea Q-Tab in real clinical practice

Authors:

Oleichik I.V., Shishkovskaia T.I., Baranov P.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11‑2): 46‑54

DOI: 10.17116/jnevro202312311246

Read: 7432 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Oleichik IV, Shishkovskaia TI, Baranov PA. Effectiveness, safety and adherence to therapy with Elicea Q-Tab in real clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(11‑2):46‑54. (In Russ.)
https://doi.org/10.17116/jnevro202312311246

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To evaluate the effectiveness and safety of escitalopram in the form of oral dispersible tablets (Elicea Q-Tab) in real-life clinical practice in patients with depressive and anxiety disorders.

MATERIAL AND METHODS

The study included 1.892 outpatient patients, 1.860 of whom completed participation in accordance with the protocol and entered the statistical analysis. Most patients were diagnosed with depressive and anxiety disorders of varying severity, as a rule, these diagnoses were established for the first time. The drug was most often prescribed at a dosage of 10 mg/day. The patients were monitored for 90 days and at each of the 3 visits, scales were used to assess the clinical condition (CGI-S and CGI-I), scales «Interaction with people, maintaining relationships (social functioning)» and «Availability of work, task completion, school attendance (professional functioning)», scales satisfaction with the convenience of admission/appointment and the effectiveness of treatment, various indicators of quality of life (autonomy, social and professional functioning, hobbies and hobbies), as well as the severity of cognitive disorders were measured.

RESULTS

Patients treated with escitalopram in the form of oral tablets dispersible in the oral cavity (Elicea Q-Tab) showed an improvement in their clinical condition (a decrease in CGI—S scores from 3.65 at visit 1 to 2.63 by visit 3, by 28%; a decrease in CGI—I scores from 2.39 at visit 1 to 1.57 to visit 3, by 34%), as well as improving the quality of life, social (from 2.74 points on 1 visit to 4.32 on 2 visits, by 58%) and professional functioning (from 2.81 on 1 visit to 4.35 on 2 visits, by 55%), the level of concentration (from 3.28 points on 1 visit up to 4.5 on 3 visits, by 37%). Doctors and patients noted high satisfaction with the effectiveness and convenience of using the drug, the frequency of adverse events was low.

CONCLUSION

The study showed that escitalopram in the form of oral tablets dispersible in the oral cavity (Elicea Q-Tab) is an efficient and safe treatment for depressive and anxiety disorders in real-world clinical settings. Patients and physicians have evaluated the drug positively and it can be considered as an effective agent in psychiatric practice.

Keywords:

oral dispersible tablets

escitalopram (Elicea Q-Tab)

SSRIs

antidepressant

adherence to therapy

depression

anxiety

psychopharmacotherapy

Authors:

Oleichik I.V.

Mental Health Research Center

ORCID: 0000-0002-8344-0620

Shishkovskaia T.I.

Mental Health Research Center

ORCID: 0000-0002-4423-4007

Baranov P.A.

Mental Health Research Center

ORCID: 0000-0002-4423-4007

Received:

14.11.2023

Accepted:

22.11.2023

Close metadata

References:

Petrova NN. Neyropsikhiatricheskie posledstviya covid-19. Juvenis Scientia. 2022;8(4):5-14. (In Russ.).
Yevtushenko EI, Panchenko DR, Tokareva AS, et al. Khronicheskiy stress voennogo vremeni kak glavnyy faktor rosta kolichestva psikhicheskikh zabolevaniy naseleniya sovremennogo Donbassa. Zhurnal Psikhiatrii i Meditsinskoy Psikhologii. 2023;2(54):97-97. (In Russ.).
Kostyuk GP. Aktualnyye problemy prakticheskoy psikhiatrii: reshit li ikh novyy Poryadok okazaniya meditsinskoy pomoshchi pri psikhicheskikh rasstroystvakh i rasstroystvakh povedeniya? Natsionalnoye Zdravookhraneniye. 2023;4(1):48-54. (In Russ.).
Bræstrup C, Sanchez C. Escitalopram: a unique mechanism of action. Int J Psychiatry Clin Pract. 2004;8:11-13.
Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001;50:345-350.
Dionisie V, Ciobanu AM, Toma VA, et al. Escitalopram Targets Oxidative Stress, Caspase-3, BDNF and MeCP2 in the Hippocampus and Frontal Cortex of a Rat Model of Depression Induced by Chronic Unpredictable Mild Stress. Int J Mol Sci. 2021;22:7483.
Rahm C, Liberg B, Kristoffersen-Wiberg M, et al. Differential Effects of Single-Dose Escitalopram on Cognitive and Affective Interference during Stroop Task. Front Psychiatry. 2014;25:5:21. https://doi.org/10.3389/fpsyt.2014.00021
Outhred T, Das P, Felmingham K, et al. Impact of acute administration of escitalopram on the processing of emotional and neutral images: a randomized crossover fMRI study of healthy women. Journal of Psychiatry & Neuroscience. 2014;39:267-275.
Komulainen E, Heikkilä R, Nummenmaa L, et al. Short-term escitalopram treatment normalizes aberrant self-referential processing in major depressive disorder. J Affect Disord. 2018;236:222-229.
Yamana M, Atake K. Blood Biological Markers for Prediction of Escitalopram Response in Patients with Major Depressive Disorder: Preliminary Study. J Depress Anxiety. 2016;5(02). https://doi.org/10.4172/2167-1044.1000222
Shinkai K, Yoshimura R, Ueda N, et al. Associations Between Baseline Plasma MHPG (3-methoxy-4-hydroxyphenylglycol) Levels and Clinical Responses With Respect to Milnacipran Versus Paroxetine Treatment. J Clin Psychopharmacol. 2004;24:11-17.
Tian S, Sun Y, Shao J, et al. Predicting escitalopram monotherapy response in depression: The role of anterior cingulate cortex. Hum Brain Mapp. 2020;41:1249-1260.
Burke WJ. Escitalopram. Expert Opin Investig Drugs. 2002;11:1477-1486.
Daboe M, Parlak C, Direm A, et al. Interaction between escitalopram and ibuprofen or paracetamol: DFT and molecular docking on the drug-drug interactions. J Biomol Struct Dyn. 2023;12:1-15.
Wade AG, Crawford GM, Young D. A survey of patient preferences for a placebo orodispersible tablet. Patient Prefer Adherence. 2012;6:201-206. https://doi.org/10.2147/PPA.S28283
Kirino E. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence. 2012;6:853-861.
Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: A meta-analysis. Curr Med Res Opin. 2009;25:161-175.
Kasper S, Spadone C, Verpillat P, et al. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol. 2006;21:105-110.
Wagner KD, Jonas J, Findling RL, et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Escitalopram in the Treatment of Pediatric Depression. J Am Acad Child Adolesc Psychiatry. 2006;45:280-288.
Emslie GJ, Ventura D, Korotzer A, et al. Escitalopram in the Treatment of Adolescent Depression: A Randomized Placebo-Controlled Multisite Trial. J Am Acad Child Adolesc Psychiatry. 2009;48:721-729.
Bose A, Li D, Gandhi C. Escitalopram in the Acute Treatment of Depressed Patients Aged 60 Years or Older. The American Journal of Geriatric Psychiatry. 2008;16:14-20.
Fonseca M, Soares JC, Hatch JP, et al. An Open Trial of Adjunctive Escitalopram in Bipolar Depression. J Clin Psychiatry. 2006;67:81-86.
Baldwin DS, Asakura S, Koyama T, et al. Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo. European Neuropsychopharmacology. 2016;26:1062-1069.
Chawla N, Anothaisintawee T, Charoenrungrueangchai K, et al. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2022;e066084.
He H, Xiang Y, Gao F, et al. Comparative efficacy and acceptability of first-line drugs for the acute treatment of generalized anxiety disorder in adults: A network meta-analysis. J Psychiatr Res. 2019;118:21-30.
Stein DJ, Wreford Andersen E, Tonnoir B, et al. Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin. 2007;23:701-711.
Qi W, Gevonden M, Shalev A. Efficacy and Tolerability of High-Dose Escitalopram in Posttraumatic Stress Disorder. J Clin Psychopharmacol. 2017;37:89-93.
Iancu I, Tschernihovsky E, Bodner E, et al. Escitalopram in the treatment of negative symptoms in patients with chronic schizophrenia: A randomized double-blind placebo-controlled trial. Psychiatry Res. 2010;179:19-23.
Kaps P, Zupanc N. Nachregistrierungssicherheitsstudie und die Wirksamkeit des Medikaments Elycea (Escitalopram) bei der Behandlung von Depressionenund Angststörungen. Psychiatrie und Psychopharmacoterapia. 2013;15:20-23.
Montgomery SA, Möller H-J. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol. 2009;24:111-118.
Kasper S. Unique mechanism of action for escitalopram: does it hold the promise? Int J Psychiatry Clin Pract. 2004;8:15-18.
Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol. 2003;18:211-217.
Barak Y. Co-prescription of antidepressants with other psychotropics: Distinct profile of escitalopram. Int J Psychiatry Clin Pract. 2008;12:31-35.
Pampallona S, Bollini P, Tibaldi G, et al. Patient adherence in the treatment of depression. British Journal of Psychiatry. 2002;180:104-109.
Sawada N, Uchida H, Suzuki T, et al. Persistence and compliance to antidepressant treatment in patients with depression: A chart review. BMC Psychiatry. 2009;9:38.
Oleychik IV, Baranov PA. Advantages of using the oral-dispersed form of escitalopram in clinical practice. Sovremennaja Terapija v Psihiatrii i Nevrologii. 2021;1:18-26. (In Russ.).
Dell’Osso B, Arici, Dobrea, et al. Escitalopram tolerability as mono-versus augmentative therapy in patients with affective disorders: a naturalistic study. Neuropsychiatr Dis Treat. 2013;9:205-209.
Llorca PM, Fernandez J-L. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract. 2007;61:702-710.
Stahl SM. Prescriber’s guide: Stahl’s essential psychopharmacology. UK. Publisher: Cambridge University, 2019;502 p
Cipriani A, Furukawa TA, Salanti G. et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746-758. https://doi.org/10.1016/S0140-6736(09)60046-5
Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol. 2014;29(4):185-196. https://doi.org/10.1097/YIC.0000000000000023
Sakurai H, Uchida H, Kato M, et al. Medical Education Panel of the Japanese Society of Clinical Neuropsychopharmacology. Pharmacological management of depression: Japanese expert consensus. J Affect Disord. 2020;266:626-632. https://doi.org/10.1016/j.jad.2020.01.149
Olejchik IV, Vladimirova TV, Kaz`mina OYu, et al. Yunosheskie e`ndogenny`e depressii (psixopatologiya, tipologiya, nozologicheskaya ocenka, lechenie). Posobie dlya vrachej. Pod red. prof. Czuczul’kovskoj M.Ya. M. 2000;34. (In Russ.).